NCT03216707

Brief Summary

Brain stimulation is a technique that can alter cortical function and thus be suitable for treating pain. This is especially when pain is chronic and associated with functional and even structural reorganization of the central nervous system. The idea of using invasive and noninvasive brain stimulation for pain relief is not new. Studies from the 1950s have investigated the brain stimulation for therapeutic use. Direct implantation of electrodes on the cerebral cortex has been carried out by Tsubokawa and colleagues in Japan. Although reported to be effective, it is invasive and involves the implantation of a foreign body into the cranium. Recent advancements in the techniques of non-invasive brain stimulation have improved and have measurable modulatory effects making this an attractive alternative for treating pain

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable pain

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 6, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 13, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2018

Completed
Last Updated

May 12, 2020

Status Verified

May 1, 2020

Enrollment Period

10 months

First QC Date

July 6, 2017

Last Update Submit

May 10, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain severity assessment using Numerical Rating Scale (NRS score from 0-100)

    we will put the capsaicin cream for 30 min at an area of 9 cm2 then we will assess the pain score throughout this time of application of the cream every 5 min

    30 min after capsaicin cream application and at the end of the HD tDCS session and one hour after study

Secondary Outcomes (1)

  • map area of sensitization caused by application of capsaicin cream

    30 min after the capsaicin cream application and at the end of HD tDCS sessionand one hour after study

Study Arms (3)

HD tDCS sham motor cortex

SHAM COMPARATOR

the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min

Device: HD tDCS sham motor cortexOther: Capsaicin cream

HD tDCS active motor cortex

ACTIVE COMPARATOR

the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min

Device: HD tDCS active motor cortexOther: Capsaicin cream

HD tDCS active insula cortex

ACTIVE COMPARATOR

the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min

Device: HD tDCS active insula cortexOther: Capsaicin cream

Interventions

the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min

HD tDCS active motor cortex

the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min

HD tDCS active insula cortex

the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min

HD tDCS sham motor cortex

Capsaicin cream

HD tDCS active insula cortexHD tDCS active motor cortexHD tDCS sham motor cortex

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to give informed consent to participate in the study.
  • Male and female University Undergraduate, Postgraduate and staff in the Department of Psychology.
  • American society of anesthesiology scores I to II patients.

You may not qualify if:

  • an adverse reaction to brain stimulation.
  • a seizure
  • an unexplained loss of consciousness
  • a stroke
  • serious head injury
  • surgery to their head
  • any brain related, neurological illnesses
  • any illness that may have caused brain injury
  • frequent or severe headaches
  • metal in your head (outside the mouth) such as shrapnel, surgical clips, or fragments from welding
  • any implanted medical devices such as cardiac pacemaker's or medical pumps
  • taking any analgesic medications in the past 24 hours
  • pregnancy
  • anyone in your family has epilepsy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saeid Elsawy

London, N15 4DW, United Kingdom

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

July 6, 2017

First Posted

July 13, 2017

Study Start

September 1, 2017

Primary Completion

June 15, 2018

Study Completion

June 15, 2018

Last Updated

May 12, 2020

Record last verified: 2020-05

Locations